Acute Treatment of Migraine With e-TNS
Launched by CEFALY TECHNOLOGY · Oct 28, 2015
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • History of episodic or chronic migraine with or without aura meeting the diagnostic criteria listed in ICHD-III beta (2013) section 1, migraine, with the exception of ''complicated migraine'' (i.e., hemiplegic migraine, basilar-type migraine, ophthalmoplegic migraine, migrainous infarction)
- • Having a migraine attack lasting at least 3 hours
- • Migraine pain intensity stabilized for at least 1 hour
- • Frontal, retro-, or peri- orbital headache.
- Exclusion Criteria:
- • Pregnant women
- • Patients having received Botox treatment in the prior 4 months
- • Patients having received supraorbital nerve blocks in the prior 4 months
- • Diagnosis of other primary or secondary headache disorders, except of Medication Overuse Headache
- • Patients with only temporal or occipital headache
- • Patients using opioid medication
- • Patients having taken abortive migraine medication in the prior 3 hours
- • Allodynia: intolerance to supraorbital neurostimulation (allodynia) that makes the treatment not applicable (the patients will be excluded if they are unable to tolerate the first 5 minutes of neurostimulation).
- • Implanted metal or electrical devices in the head
- • Cardiac pacemaker or implanted or wearable defibrillator
- • Patient having had a previous experience with Cefaly®
About Cefaly Technology
Cefaly Technology is a pioneering company dedicated to advancing the field of neuromodulation for the management of chronic pain, particularly migraines. With a strong focus on innovative solutions, Cefaly Technology develops non-invasive medical devices that leverage electrical stimulation to alleviate migraine symptoms and improve patient quality of life. Committed to rigorous scientific research and clinical validation, the company aims to provide effective, user-friendly alternatives to traditional pharmacological treatments, empowering patients to take control of their migraine management. Through ongoing clinical trials and collaborations, Cefaly Technology strives to enhance understanding and treatment of headache disorders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
New Haven, Connecticut, United States
New York, New York, United States
Lenexa, Kansas, United States
Patients applied
Trial Officials
Denise Chou, M.D.
Principal Investigator
Columbia University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials